What to Do When a Patient Discloses Nonapproved Drug Use: A Pharmacist’s Guide
A patient quietly mentions that they have been injecting something they bought online. The moment that follows determines whether they get useful care or learn to stop telling health professionals anything. Here is a structured way to handle it.
1. Start Without Judgement
Shame ends conversations. A patient who feels judged will minimise, omit, and stop disclosing. The opening response should be neutral and practical: thank them for telling you, and make clear that the information helps you keep them safe. That is not a soft skill. It is the mechanism by which you get accurate information.
2. Gather the Essentials
Ask systematically, and write it down.
- What — the product name, and whether they know the actual peptide.
- Where from — the source, even if only a website or messaging handle.
- How much — the dose, and critically, how they measure it.
- How — injection route, frequency, and technique.
- How long — duration of use and any dose changes.
- What else — other peptides, supplements, or prescription medicines, including anything obtained elsewhere.
Peptide stacking is common, and a patient may not think to mention the second or third product.
3. Screen for Symptoms That Need Urgent Attention
Some findings change the encounter from counselling to referral. Ask directly about:
- Palpitations, chest pain, or a resting heart rate that feels unusually fast.
- Severe or persistent vomiting, and inability to keep fluids down.
- Symptoms of hypoglycaemia — sweating, tremor, confusion, palpitations.
- Redness, swelling, warmth, or discharge at an injection site, or fever.
- Visual changes, particularly in a patient with diabetes.
- Severe abdominal pain radiating to the back, which may suggest pancreatitis.
Any of these warrants prompt medical assessment.
4. Counsel on What Is Actually Knowable
Do not overstate certainty in either direction. The honest counselling points are that the product identity, purity, and dose cannot be verified; that reconstitution errors are easy to make and can be large; that combining compounds increases risk without any data on the combination; and that storage and sterility requirements for injectables are easy to get wrong at home.
Where an approved alternative exists and is appropriate, say so plainly. Where it does not, say that too.
5. Document the Disclosure
Record what the patient reported, in their own terms, in the medication record. This matters for continuity of care and for any future clinical decision. It also normalises the disclosure so that the next professional who reads the record does not have to rediscover it.
6. Report Suspected Adverse Events
Report to the national pharmacovigilance system. In the United States, that is MedWatch; most countries have an equivalent. Reports about unapproved products are particularly valuable because this population generates almost no routine data. Even an uncertain report contributes, because pattern detection needs volume.
7. The Bottom Line
The patient has already made the decision to use an unapproved product. Your influence lies in what happens next: whether they get screened for serious complications, whether they receive accurate information about the uncertainties, whether they are documented, and whether their experience reaches the system that could protect the next person. All four depend on the conversation going well.
Disclaimer: This article is for informational and educational purposes only. It is not medical advice and is not a substitute for consultation with a qualified healthcare professional. Never start, stop, or change a medicine without guidance from your prescriber or pharmacist.
References:
- Sehgal NKR, Tronieri JS, Rader B, Ungar L, Guntuku SC. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Netw Open. 2026;9(10):e2638929. doi:10.1001/jamanetworkopen.2026.38929
- US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. FDA.gov. Accessed October 2026. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
- Nagem Lopes LP, Ramos-Silva A, Gallo de Castro A, Correa de Matos G. Potential utility of social media in pharmacovigilance to identify adverse events and safety signals: a scoping review. Res Social Adm Pharm. 2026;22(5):617-624. doi:10.1016/j.sapharm.2026.02.003
